Tags

Type your tag names separated by a space and hit enter

Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis.
J Gastroenterol Hepatol 2015; 30(9):1412-9JG

Abstract

BACKGROUND AND AIM

It has been reported that the branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is a useful indicator of liver function and BCAA therapy is associated with a decreased incidence of hepatocellular carcinoma (HCC). However, there has not been sufficient research on the relationship between BTR and the effects of BCAA therapy after initial treatment of HCC. We investigated the impact of BTR and BCAA therapy on survival in patients with HCC.

METHODS

A total of 315 patients with HCC who were treated (n = 66) or not treated (n = 249) with BCAA were enrolled; of these, 66 were selected from each group using propensity score matching. Survival from liver-related mortality was analyzed.

RESULTS

In patients who did not receive BCAA therapy (n = 249), multivariate analysis for factors associated with survival indicated that low BTR (≤ 4.4) was independently associated with poor prognosis in patients with HCC (hazard ratio, 1.880; 95% confidence interval, 1.125-3.143; P = 0.016). In addition, among patients selected by propensity score matching (n = 132), multivariate analysis indicated that BCAA therapy was independently associated with good prognosis in patients with HCC (hazard ratio, 0.524; 95% confidence interval, 0.282-0.973; P = 0.041). BTR was not significantly associated with survival.

CONCLUSIONS

Intervention involving BCAA therapy improved survival in patients with HCC versus untreated controls, regardless of BTR. In addition, low BTR was associated with poor prognosis in patients who did not receive BCAA therapy.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25799910

Citation

Tada, Toshifumi, et al. "Impact of the Branched-chain Amino Acid to Tyrosine Ratio and Branched-chain Amino Acid Granule Therapy in Patients With Hepatocellular Carcinoma: a Propensity Score Analysis." Journal of Gastroenterology and Hepatology, vol. 30, no. 9, 2015, pp. 1412-9.
Tada T, Kumada T, Toyoda H, et al. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. J Gastroenterol Hepatol. 2015;30(9):1412-9.
Tada, T., Kumada, T., Toyoda, H., Kiriyama, S., Tanikawa, M., Hisanaga, Y., ... Yama, T. (2015). Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. Journal of Gastroenterology and Hepatology, 30(9), pp. 1412-9. doi:10.1111/jgh.12954.
Tada T, et al. Impact of the Branched-chain Amino Acid to Tyrosine Ratio and Branched-chain Amino Acid Granule Therapy in Patients With Hepatocellular Carcinoma: a Propensity Score Analysis. J Gastroenterol Hepatol. 2015;30(9):1412-9. PubMed PMID: 25799910.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. AU - Tada,Toshifumi, AU - Kumada,Takashi, AU - Toyoda,Hidenori, AU - Kiriyama,Seiki, AU - Tanikawa,Makoto, AU - Hisanaga,Yasuhiro, AU - Kanamori,Akira, AU - Kitabatake,Shusuke, AU - Yama,Tsuyoki, PY - 2015/03/11/accepted PY - 2015/3/25/entrez PY - 2015/3/25/pubmed PY - 2016/4/5/medline KW - branched-chain amino acid granules KW - branched-chain amino acid to tyrosine ratio KW - hepatocellular carcinoma KW - propensity score SP - 1412 EP - 9 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 30 IS - 9 N2 - BACKGROUND AND AIM: It has been reported that the branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is a useful indicator of liver function and BCAA therapy is associated with a decreased incidence of hepatocellular carcinoma (HCC). However, there has not been sufficient research on the relationship between BTR and the effects of BCAA therapy after initial treatment of HCC. We investigated the impact of BTR and BCAA therapy on survival in patients with HCC. METHODS: A total of 315 patients with HCC who were treated (n = 66) or not treated (n = 249) with BCAA were enrolled; of these, 66 were selected from each group using propensity score matching. Survival from liver-related mortality was analyzed. RESULTS: In patients who did not receive BCAA therapy (n = 249), multivariate analysis for factors associated with survival indicated that low BTR (≤ 4.4) was independently associated with poor prognosis in patients with HCC (hazard ratio, 1.880; 95% confidence interval, 1.125-3.143; P = 0.016). In addition, among patients selected by propensity score matching (n = 132), multivariate analysis indicated that BCAA therapy was independently associated with good prognosis in patients with HCC (hazard ratio, 0.524; 95% confidence interval, 0.282-0.973; P = 0.041). BTR was not significantly associated with survival. CONCLUSIONS: Intervention involving BCAA therapy improved survival in patients with HCC versus untreated controls, regardless of BTR. In addition, low BTR was associated with poor prognosis in patients who did not receive BCAA therapy. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/25799910/Impact_of_the_branched_chain_amino_acid_to_tyrosine_ratio_and_branched_chain_amino_acid_granule_therapy_in_patients_with_hepatocellular_carcinoma:_A_propensity_score_analysis_ L2 - https://doi.org/10.1111/jgh.12954 DB - PRIME DP - Unbound Medicine ER -